000135785 001__ 135785
000135785 005__ 20240614091948.0
000135785 0247_ $$2doi$$a10.1016/j.ijbiomac.2024.132563
000135785 0248_ $$2sideral$$a138750
000135785 037__ $$aART-2024-138750
000135785 041__ $$aeng
000135785 100__ $$0(orcid)0000-0003-1599-8216$$aLanda, Guillermo
000135785 245__ $$aPLGA nanoparticle-encapsulated lysostaphin for the treatment of Staphylococcus aureus infections
000135785 260__ $$c2024
000135785 5060_ $$aAccess copy available to the general public$$fUnrestricted
000135785 5203_ $$aStaphylococcus aureus possesses the ability to become pathogenic, leading to severe and life-threatening infections. Its methicillin-resistant variant MRSA has garnered high-priority status due to its increased morbidity and associated mortality. This emphasizes the urgency for novel anti-staphylococcal agents. The bacteriocin lysostaphin stands out for its remarkable bactericidal activity against S. aureus, including MRSA, outperforming conventional antibiotics. However, the clinical application of lysostaphin faces challenges, including enzymatic activity loss under physiological conditions and potential immunogenicity. This study introduces a novel approach by encapsulating lysostaphin within polylactic-co-glycolic acid (PLGA) nanoparticles, a biodegradable copolymer known for its biocompatibility and sustained drug release ability. The study assesses the antimicrobial activity of lysostaphin-loaded PLGA nanoparticles against different S. aureus strains, and we also used GFP-expressing S. aureus for facilitating its traceability in planktonic, biofilm, and intracellular infection models. The results showed the significant reduction in bacteria viability both in planktonic and biofilm states. The in vitro intracellular infection model demonstrated the significantly enhanced efficiency of the developed nanoparticles compared to the treatment with the free bacteriocin. This research presents lysostaphin encapsulation within PLGA nanoparticles and offers promising avenues for enhancing lysostaphin's therapeutic efficacy against S. aureus infections.
000135785 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/MS19-00092$$9info:eu-repo/grantAgreement/ES/MCINN/PRE2018-085769$$9info:eu-repo/grantAgreement/ES/MICINN/PDC2021-121405-I00$$9info:eu-repo/grantAgreement/ES/MICINN/PID2020-113987RB-I00
000135785 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000135785 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000135785 700__ $$0(orcid)0000-0002-5309-7796$$aAguerri, Laura$$uUniversidad de Zaragoza
000135785 700__ $$0(orcid)0000-0002-2966-9088$$aIrusta, Silvia
000135785 700__ $$0(orcid)0000-0003-2293-363X$$aMendoza, Gracia
000135785 700__ $$0(orcid)0000-0003-3165-0156$$aArruebo, Manuel$$uUniversidad de Zaragoza
000135785 7102_ $$12009$$2750$$aUniversidad de Zaragoza$$bDpto. Química Analítica$$cÁrea Química Analítica
000135785 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000135785 773__ $$g271, Part 1 (2024), 132563 [11 pp.]$$pInt. j. biol. macromol.$$tInternational journal of biological macromolecules$$x0141-8130
000135785 8564_ $$s5405372$$uhttps://zaguan.unizar.es/record/135785/files/texto_completo.pdf$$yVersión publicada
000135785 8564_ $$s2534872$$uhttps://zaguan.unizar.es/record/135785/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000135785 909CO $$ooai:zaguan.unizar.es:135785$$particulos$$pdriver
000135785 951__ $$a2024-06-14-09:00:21
000135785 980__ $$aARTICLE